Medical Access and Reimbursement in Poland

Psilocybin and psilocin are treated as Group I-P psychotropic substances. Under the Polish framework, that supports research-only use rather than routine medical prescribing or reimbursement. # #

MDMA remains controlled in Poland and no authorised medical or public reimbursement route was identified. Lawful use should be treated as limited to authorised research. # # #

Esketamine is the clearest Polish patient-access route. Spravato is EU-authorised and Polish procurement/reimbursement evidence identifies esketamine as reimbursed under drug programme B.147 for treatment-resistant depression. # # #

Ketamine is listed separately from Group I-P psychedelics and can be used medically, but Polish psychiatric use for depression remains off-label. Reviewed sources did not show a national public reimbursement route for antidepressant ketamine. # # #

DMT remains controlled in Poland. No authorised routine medical access or reimbursement pathway was identified outside approved research. # #

5-MeO-DMT is not a routine Polish treatment. Poland is relevant through research links, including the GH001 mebufotenin publication with Medical University of Gdansk authorship, but this does not create patient access. # # #

No Polish authorised ibogaine treatment, reimbursement route or strong country-specific clinical programme was identified in the reviewed sources. # #

No Polish authorised medical or reimbursement route for ayahuasca was identified. DMT-related controls and the lack of a specific access pathway mean it should be treated as unavailable outside authorised research. # #

Mescaline remains a controlled psychotropic substance. No authorised medical or reimbursement pathway was identified outside approved research. #

2C-family substances remain controlled in Poland. No authorised treatment or reimbursement route was identified in the reviewed sources. #